Air Canada will release its third quarter 2026 financial results before holding a conference call with analysts on October 29, 2026, at 5:30 p.m. ET. Key executives including the CFO and Commercial Officer will discuss the results and answer questions. The call will also include a session for term loan B lenders and bondholders. The event is open to the public as a listen-only webcast, with a replay available afterward on Air Canada's investor website.
Air Canada's upcoming third quarter 2026 results are announced ahead of its October 29 conference call. For readers following Industrials-sector stocks on Pluang as of Oct 13, 2026 19:43 WIB, 56 of 113 stocks rose while 52 fell. MasTec Inc (MTZ) at USD 202.71 saw a 2.00% decline with 100% sell orders, contrasting with SMX Security Matters plc (SMX) at USD 3.55 which dropped 1.93% but had 100% buy orders, and Powell Industries (POWL) at USD 181.69 fell 1.99% with a notably shorter typical hold time of 6 days compared to MTZ's 24 days and SMX's 22 days.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
